S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
OTCMKTS:OPHLF

Ono Pharmaceutical (OPHLF) Stock Forecast, Price & News

$27.08
0.00 (0.00%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$27.08
$27.08
50-Day Range
$24.62
$27.08
52-Week Range
$20.57
$27.08
Volume
20 shs
Average Volume
7,689 shs
Market Capitalization
$13.92 billion
P/E Ratio
17.81
Dividend Yield
N/A
Beta
0.34
30 days | 90 days | 365 days | Advanced Chart
Receive OPHLF News and Ratings via Email

Sign-up to receive the latest news and ratings for Ono Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Ono Pharmaceutical logo

About Ono Pharmaceutical

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson's disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and collaboration agreement with Numab Therapeutics AG and Caris Life Sciences, Inc. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:OPHLF
Employees
3,607
Year Founded
N/A

Sales & Book Value

Annual Sales
$2.92 billion
Cash Flow
$1.32 per share

Profitability

Net Income
$708.99 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$13.92 billion
Optionable
Not Optionable

Company Calendar

Today
5/21/2022
Fiscal Year End
3/31/2023

MarketRank

Overall MarketRank

1.17 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -













Ono Pharmaceutical (OTCMKTS:OPHLF) Frequently Asked Questions

Are investors shorting Ono Pharmaceutical?

Ono Pharmaceutical saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 806,300 shares, an increase of 22.4% from the April 15th total of 658,600 shares. Based on an average daily trading volume, of 15,400 shares, the short-interest ratio is presently 52.4 days.
View Ono Pharmaceutical's Short Interest
.

Who are Ono Pharmaceutical's key executives?
Ono Pharmaceutical's management team includes the following people:
  • Mr. Gyo Sagara, CEO, Pres & Representative Director (Age 64)
  • Mr. Shozo Matsuoka Ph.D., Corp. Exec. Officer and Exec. Director of Corp. Regulatory Compliance, Safety & QA
  • Yukio Tani, Corp. Exec. Officer & Head of Corp. Communications
  • Katsuji Teranishi, Corp. Officer and Chief Officer of Sales, Mkt, Wholesales Mgt., Planning & Primary Care Bus. Div.
  • Mr. Isao Ono, Exec. Officer, Director of Corp. Research & Director (Age 63)
  • Mr. Hiroshi Ichikawa, Corp. Officer & Sr. Director of Medical External Affairs
  • Mr. Toichi Takino Ph.D., Sr. Exec. Officer, Exec. Director of Discovery & Research and Director (Age 54)
  • Mr. Toshihiro Tsujinaka, Sr. Exec. Officer, Exec. Director of Corp. Strategy & Planning and Director (Age 58)
  • Hiromu Habashita Ph.D., Corp. Officer and Deputy Exec. Director of Discovery & Research Division
  • Kiyoaki Idemitsu, Exec. Officer, Exec. Director of Clinical Devel. & Director (Age 58)
What is Ono Pharmaceutical's stock symbol?

Ono Pharmaceutical trades on the OTCMKTS under the ticker symbol "OPHLF."

How do I buy shares of Ono Pharmaceutical?

Shares of OPHLF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ono Pharmaceutical's stock price today?

One share of OPHLF stock can currently be purchased for approximately $27.08.

How much money does Ono Pharmaceutical make?

Ono Pharmaceutical has a market capitalization of $13.92 billion and generates $2.92 billion in revenue each year. The company earns $708.99 million in net income (profit) each year or $1.519990 on an earnings per share basis.

How many employees does Ono Pharmaceutical have?

Ono Pharmaceutical employs 3,607 workers across the globe.

What is Ono Pharmaceutical's official website?

The official website for Ono Pharmaceutical is www.ono.co.jp.

How can I contact Ono Pharmaceutical?

Ono Pharmaceutical's mailing address is 8-2 Kyutaromachi 1-chome Chuo-ku, Osaka M0, 541-8564. The company can be reached via phone at (166) 263-5670 or via fax at 816-6263-2950.

This page was last updated on 5/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.